As part of Aamal’s ongoing commitment to global investor engagement, CEO Mr. Rashid Ali Almansoori held high-level meetings with leading international investment and asset management firms to explore value-driven growth opportunities.
As part of Aamal Company’s continued efforts to strengthen global investor relations, CEO Mr. Rashid Ali Almansoori recently held a series of high-level meetings with some of the world’s leading investment and asset management firms. These strategic engagements reflect Aamal’s commitment to fostering open dialogue with the international investment community and exploring opportunities for sustainable, value-driven growth.
"Aamal" has a remarkable presence in "Project Qatar 2025" exhibition
"Aamal" has a remarkable presence in "Project Qatar 2025" exhibition, reaffirming its commitment to driving industrial innovation and supporting Qatar’s sustainable development goals through its diversified business operations and strategic vision.
Sheikh Mohammed bin Faisal Al Thani participated in the media roundtable, where he highlighted the company’s strategic priorities, growth outlook, and continued alignment with Qatar’s economic diversi
Sheikh Mohammed bin Faisal Al Thani, Vice Chairman and Managing Director of Aamal Company, participated in the media roundtable, where he highlighted the company’s strategic priorities, growth outlook, and continued alignment with Qatar’s economic diversification goals.
Aamal Signs Over QAR 1 Billion Contract with Kahramaa Awarded Last Year to Elsewedy Cables
Aamal Signs Over QAR 1 Billion Contract with Kahramaa Awarded Last Year to Elsewedy Cables Qatar, where Elsewedy Cables will begin preparations to receive supply and project orders as part of the expansion of Kahramaa’s power transmission system in Qatar.
Aamal's subsidiary, Ebn Sina Medical, strengthened commitment to healthcare innovation through their continued partnership with Novo Nordisk to bring Wegovy® (Semaglutide 2.4mg) to Qatar.
Aamal's subsidiary, Ebn Sina Medical, strengthened commitment to healthcare innovation through their continued partnership with Novo Nordisk to bring Wegovy® (Semaglutide 2.4mg) to Qatar.